Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their target price on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Evogene Stock Performance

Shares of NASDAQ EVGN opened at $2.24 on Friday. Evogene has a 1 year low of $2.02 and a 1 year high of $10.40. The firm has a market cap of $9.89 million, a P/E ratio of -0.57 and a beta of 1.40. The stock has a fifty day moving average price of $2.81 and a two-hundred day moving average price of $4.99.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The firm had revenue of $0.91 million for the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.